Pelletier Jean-Pierre, Boileau Christelle, Brunet Julie, Boily Martin, Lajeunesse Daniel, Reboul Pascal, Laufer Stefan, Martel-Pelletier Johanne
Osteoarthritis Research Unit, Centre Hospitalier de l'Université de Montreal, Hôpital Notre-Dame, Montreal, Quebec, Canada H2L 4M1.
Bone. 2004 Mar;34(3):527-38. doi: 10.1016/j.bone.2003.11.021.
To evaluate the morphological changes that take place in the subchondral bone and calcified cartilage zone in the experimental anterior cruciate ligament (ACL) dog model of osteoarthritis (OA) and analyze concomitant changes in the level of MMP-13 and cathepsin K, as well as examine the therapeutic effects of licofelone, a lipoxygenase (LO)/cyclooxygenase (COX) inhibitor, on these morphological and biochemical changes.
Experimental group 1 underwent sectioning of the ACL of the right knee with no active treatment (placebo group). Experimental groups 2 and 3 underwent sectioning of the ACL of the right knee and were administered therapeutic concentrations of licofelone (2.5 or 5.0 mg/kg/day p.o., respectively) for 8 weeks, beginning the day following surgery. Group 4 consisted of untreated dogs used as normal control. Specimens of subchondral bone including the calcified cartilage were selected from lesional and non-lesional areas of OA tibial plateaus. Specimens were processed for static morphometric analysis and immunohistochemical analysis for MMP-13 and cathepsin K.
As indicated by a reduction in bone surface and trabecular thickness, a significant loss of subchondral bone occurred in OA dogs. These changes were associated with an increased level of MMP-13 synthesis by bone cells and an increase in the osteoclast population that stained strongly positive for cathepsin K and MMP-13. Changes were much more pronounced in the specimens taken from the lesional areas. Treatment with licofelone decreased, in a dose-dependent manner, the OA bone morphological changes at the same time it reduced the level of MMP-13 in bone cells and the number of cathepsin K and MMP-13 positive osteoclasts.
Increased bone loss and bone resorption is associated with the development of OA cartilage lesions. Licofelone treatment was found to prevent the morphological and biochemical changes seen in early experimental OA effectively. These findings may help explain the mechanisms by which this drug could exert its possible effect on the development of OA.
评估实验性前交叉韧带(ACL)损伤犬骨关节炎(OA)模型中软骨下骨和钙化软骨区发生的形态学变化,分析基质金属蛋白酶-13(MMP-13)和组织蛋白酶K水平的伴随变化,并研究脂氧合酶(LO)/环氧化酶(COX)抑制剂利考昔芬对这些形态学和生化变化的治疗效果。
实验组1对右膝前交叉韧带进行切断且不进行积极治疗(安慰剂组)。实验组2和3对右膝前交叉韧带进行切断,并在术后次日开始给予治疗浓度的利考昔芬(分别为2.5或5.0mg/kg/天,口服),持续8周。第4组由未治疗的犬组成,作为正常对照。从OA胫骨平台的病变和非病变区域选取包括钙化软骨的软骨下骨标本。对标本进行静态形态计量分析以及MMP-13和组织蛋白酶K的免疫组织化学分析。
如骨表面和小梁厚度的减少所示,OA犬的软骨下骨出现显著丢失。这些变化与骨细胞中MMP-13合成水平的增加以及组织蛋白酶K和MMP-13染色呈强阳性的破骨细胞数量增加有关。在取自病变区域的标本中,变化更为明显。利考昔芬治疗以剂量依赖性方式减少了OA骨形态学变化,同时降低了骨细胞中MMP-13的水平以及组织蛋白酶K和MMP-13阳性破骨细胞的数量。
骨丢失和骨吸收增加与OA软骨损伤的发展相关。发现利考昔芬治疗可有效预防早期实验性OA中出现的形态学和生化变化。这些发现可能有助于解释该药物对OA发展可能产生作用的机制。